Full Text
EE452 Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine

Abstract

Authors

Matthijs M. Versteegh Simone A. Huygens

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×